Patents by Inventor Hankun Zhang

Hankun Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210139497
    Abstract: Disclosed by the present invention are a thienocyclic compound represented by formula (I), a pharmaceutically acceptable salt or a hydrate thereof, a composition containing the thienocyclic compound, and a preparation method therefor.
    Type: Application
    Filed: November 23, 2018
    Publication date: May 13, 2021
    Applicant: SHANGHAI YUYAO BIOTECH LTD.
    Inventors: Hankun ZHANG, Weiqiang LU, Mingyao LIU, Junjie YANG, Weiwei YU, Longlong HU, Xinpei ZHANG, Xianhua LIN, Wenjuan LIU, Zaixi XI
  • Patent number: 8168647
    Abstract: The invention provides vinblastine derivatives represented by the following formula 1 or their physiologically acceptable salts, their preparation, use and pharmaceutical compositions comprising the said derivatives. The said vinblastine derivatives show inhibiting activities against tumor cell lines and can be used as medicaments for treating malignant tumors.
    Type: Grant
    Filed: December 17, 2007
    Date of Patent: May 1, 2012
    Assignee: Shanghai Institute of Materia Medica Chinese Academy of Sciences
    Inventors: Lihong Hu, Xu Shen, Hualiang Jiang, Liguang Lou, Hong Ding, Yong Shao, Hankun Zhang
  • Publication number: 20100113494
    Abstract: The present invention provides 13,13a-dihydroberberine derivatives or their physiologically acceptable salts represented by the following formula, pharmaceutical compositions comprising the same, and uses thereof. The 13,13a-dihydroberberine derivatives have an activity of promoting glucose absorption in muscle cells, and the whole animal tests show that the present compounds have effects on improving glucose-tolerance and insulin-resistance, facilitating weight loss, relieving fatty liver and the like. Thus, the present compounds can be used in treating diabetes mellitus, adiposity, fatty liver and complications thereof induced by insulin resistance.
    Type: Application
    Filed: September 30, 2007
    Publication date: May 6, 2010
    Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Lihong Hu, Jia Li, Jingya Li, Hankun Zhang, Zhe Cheng, Jiming Ye, David E. James, Edward W. Kraegen